Lung Cancers Today
Advertisement
However, the study findings presented at STS 2025 suggest that segmentectomy may be a “viable alternative” to lobectomy.
Despite decades of decline, "lung cancer continues to dwarf other cancers in the number of deaths," officials said.
Dr. Liu discusses remaining questions, key considerations, and how the data might shape the field moving forward.
The approval is for the first-line treatment of advanced NSCLC with EGFR exon 19 deletions or exon 21 L858R substitutions.
The ORR of the external control group was 3%, while it was 36.8% in those who received amivantamab for NSCLC.
Learn how sublobar resection showed "comparable oncologic outcomes and complication rates" as lobectomy per a recent review.
The FDA action date for its regulatory decision is anticipated during the third quarter of this year.
Dr. Liu shares his insights on the recent announcement that the phase 3 trial met its secondary endpoint of overall survival.
A team integrating clinical, dual-energy spectral computed tomography, and radiomics features into a predictive model.
The phase 2 trial included patients who had advanced or metastatic NSCLC with actionable genomic alterations.
Sunvozertinib is an irreversible EGFR inhibitor that targets a wide spectrum of EGFR mutations.
Glecirasib, also known as JAB-21822, is an oral, covalent KRAS G12C inhibitor.
For patients with NSCLC and EGFR mutations, amivantamab plus carboplatin-pemetrexed shows OS benefits versus chemo alone.
The improvement in median OS with the combination treatment is “expected to exceed one year," officials said.
The study showed there was “preliminary evidence of central nervous system-anti-tumor activity” in some patients.
The TROPiCS-03 trial, a multicohort, open-label basket study, is assessing the antibody-drug conjugate in solid tumors.
The therapy is now the “first and only subcutaneously administered PD-1 inhibitor," officials said in an announcement.
Lauren Averett Byers, MD, will be honored with the award during the TAMEST Annual Conference in February.
The foundation's 2024 Scientific Grant Program awards mark the "largest single-year investment in its history.”
Home-based exercise programs after lung cancer resection do not improve physical function in patients with NSCLC.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.